Evidence map›Paper›PMID 39225560›Full record

ArticleNanomedicine (London, England)2024

Mapping global research landscape and trend of nano-drug delivery system for urological cancers: a bibliometric analysis.

Yibo Shi, Zean Fu, Xinyi Yu, Yuanfeng Zhang, Guangrui Fan, Zhiping Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yibo ShiInstitute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou, China.ORCID 0000-0003-1523-6801
Zean FuClinical School of Cardiovascular Disease, Tianjin Medical University, Tianjin, China.ORCID 0000-0002-7945-5600
Xinyi YuDepartment of Cardiovascular Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.ORCID 0000-0003-3118-4407
Yuanfeng ZhangInstitute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou, China.ORCID 0000-0002-4330-072X
Guangrui FanInstitute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou, China.ORCID 0000-0002-0865-8080
Zhiping WangInstitute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou, China.ORCID 0000-0002-8140-591X

Funding

The Cuiying Plan Project of the Lanzhou University Second Hospital PR0103031The National Natural Science Foundation of China 051160007
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BibliometricsUrologic NeoplasmsAntineoplastic AgentsDrug Delivery SystemsHumansNanomedicineNanoparticle Drug Delivery SystemAntineoplastic AgentsNanoparticle Drug Delivery Systembibliometric analysisbladder cancernanodrug delivery systemsprostate cancerrenal cancer

Identifiers

PMID39225560
PMCPMC11485865

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.